Revenue: As of FY2026 Q1, the actual value is USD 300 K.

EPS: As of FY2026 Q1, the actual value is USD -0.05, meeting the estimate of USD -0.05.

EBIT: As of FY2026 Q1, the actual value is USD -2.209 M.

License Revenue

License Revenue was $300,000 for the three months ended March 31, 2026, compared to $0 for the three months ended March 31, 2025 .

Operating Costs and Expenses

• General and administrative expenses increased to $2.1 million for the three months ended March 31, 2026, from $1.4 million for the three months ended March 31, 2025, representing a 43% increase, primarily due to higher legal fees, investor relations costs, registration fees, and salary costs . Stock-based compensation expense for general and administrative expenses was $111,000 for Q1 2026, up from $54,000 for Q1 2025 .
• Research and development expenses decreased to $355,000 for the three months ended March 31, 2026, from approximately $3.0 million for the three months ended March 31, 2025, an 88% decrease, mainly due to lower clinical trial expenses following the completion of the VIRAGE Phase 2b trial of VCN-01 in PDAC, the recognition of the Spanish R&D rebate, and lower indirect compensation costs, partially offset by higher patent expenses for SYN-020 . Stock-based compensation expense for research and development was $24,000 for Q1 2026, down from $46,000 for Q1 2025 .
• Total Operating Costs and Expenses were $2.427 million for Q1 2026, compared to $4.417 million for Q1 2025 .

Loss from Operations

Loss from Operations was - $2.127 million for the three months ended March 31, 2026, compared to - $4.417 million for the three months ended March 31, 2025 .

Other Income

Total Other Income was $83,000 for the three months ended March 31, 2026, compared to $93,000 for the three months ended March 31, 2025 . This included $82,000 in interest income and a $1,000 exchange gain for Q1 2026, while Q1 2025 included $96,000 in interest income and a - $3,000 exchange loss .

Net Loss Attributable to Common Stockholders

Net Loss Attributable to Common Stockholders was - $2.044 million for the three months ended March 31, 2026, compared to - $4.324 million for the three months ended March 31, 2025 .

Cash and Cash Equivalents

Cash and cash equivalents totaled $14.4 million as of March 31, 2026, an increase of $1.4 million from December 31, 2025 . Theriva Biologics, Inc. reported a cash runway into Q1 2027 .

Operational Outlook

Theriva Biologics, Inc. plans a small dosing feasibility study in Spain for VCN-01 in PDAC in the second half of 2026 and aims for potential first patient enrollment in a Phase ²⁄₃ clinical trial for VCN-01 in retinoblastoma in December 2026 . Rolling Biologic Licensing Application submissions are targeted for 2029, with approval sought before September 30, 2029 . Research and development expenses are anticipated to decrease in the near future until additional clinical trials commence .